NCT03585517View on ClinicalTrials.gov

Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 21, 2018

Primary Completion Date

August 1, 2020

Study Completion Date

October 1, 2020

Conditions
AML
Interventions
DRUG

IM23

T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor

Trial Locations (1)

Unknown

Xian Lu, Beijing

All Listed Sponsors
lead

Beijing Immunochina Medical Science & Technology Co., Ltd.

INDUSTRY

NCT03585517 - Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T) | Biotech Hunter | Biotech Hunter